Article révisé par les pairs
Résumé : Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT)-Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT-Lymphoma (p ≤ 0.05), FACT-General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3. The estimated difference in health state utilities for treatment response and progressive disease was both statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001). Conclusion: In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities.

Documents en relation

DI-fusion

  • The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
    par Zijlstra, Josée J.M. , Follows, George , Casasnovas, René Olivier , Vermaat, Joost J.S.P. , Kalakonda, Nagesh , Choquet, Sylvain , Hill, Brian , Thieblemont, Catherine , Cavallo, Federica , De la Cruz, Fátima , Kuruvilla, John , Hamad, Nada , Jäger, Ulrich , Caimi, Paolo , Gurion, Ronit , Warzocha, Krzysztof , Bakhshi, Sameer , Sancho, Juan Manuel , Schuster, Michael , Egyed, Miklos , Offner, Fritz , Vassilakopoulos, Theodoros , Samal, Priyanka , Ku, Matthew , Xu, Jenny , Corona, Kelly , Chamoun, Kamal , Shah, Jatin , Canales, Miguel , Maerevoet, Marie
    Publication 2022-02
  • Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
    par Schuster, Michael , Zijlstra, Josée J.M. , Casasnovas, René Olivier , Vermaat, Joost J.S.P. , Kalakonda, Nagesh , Goy, Andre , Choquet, Sylvain , Neste, Eric Van Den , Hill, Brian , Thieblemont, Catherine , Cavallo, Federica , De la Cruz, Fátima , Kuruvilla, John , Hamad, Nada , Jäger, Ulrich , Caimi, Paolo , Gurion, Ronit , Warzocha, Krzysztof , Bakhshi, Sameer , Sancho, Juan Manuel , Follows, George , Egyed, Miklos , Offner, Fritz , Vassilakopoulos, Theodoros , Samal, Priyanka , Ku, Matthew , Ma, Xiwen , Corona, Kelly , Chamoun, Kamal , Shah, Jatin , Shacham, Sharon , Kauffman, Michael , Canales, Miguel , Maerevoet, Marie
    Publication 2022
  • Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
    par Maerevoet, Marie , Zijlstra, Josée J.M. , Follows, George , Casasnovas, René Olivier , Vermaat, Joost J.S.P. , Kalakonda, Nagesh , Goy, Andre , Choquet, Sylvain , Van Den Neste, Eric , Hill, Brian , Thieblemont, Catherine , Cavallo, Federica , De la Cruz, Fátima , Kuruvilla, John , Hamad, Nada , Jaeger, Ulrich , Caimi, Paolo , Gurion, Ronit , Warzocha, Krzysztof , Bakhshi, Sameer , Sancho, Juan Manuel , Schuster, Michael , Egyed, Miklos , Offner, Fritz , Vassilakopoulos, Theodoros , Samal, Priyanka , Ku, Matthew , Ma, Xiwen , Corona, Kelly , Chamoun, Kamal , Shah, Jatin , Shacham, Sharon , Kauffman, Michael , Canales, Miguel
    Publication 2021-12
  • Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes
    par Casasnovas, René Olivier , Follows, George , Zijlstra, Josée J.M. , Vermaat, Joost J.S.P. , Kalakonda, Nagesh , Choquet, Sylvain , Neste, Eric Van Den , Hill, Brian , Thieblemont, Catherine , Cavallo, Federica , La Cruz, Fátima De , Kuruvilla, John , Hamad, Nada , Jaeger, Ulrich , Caimi, Paolo , Gurion, Ronit , Warzocha, Krzysztof , Bakhshi, Sameer , Sancho, Juan Manuel , Schuster, Michael , Egyed, Miklos , Offner, Fritz , Vassilakopoulos, Theodoros , Samal, Priyanka , Ku, Matthew , Ma, Xiwen , Chamoun, Kamal , Shah, Jatin , Canales, Miguel , Maerevoet, Marie , Shacham, Sharon , Kauffman, Michael , Goy, Andre
    Publication 2021
  • Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
    par Kalakonda, Nagesh , Maerevoet, Marie , Cavallo, Federica , Follows, George , Goy, Andre , Vermaat, Joost J.S.P. , Casasnovas, Olivier , Hamad, Nada , Zijlstra, Josée J.M. , Bakhshi, Sameer , Bouabdallah, Reda , Choquet, Sylvain , Gurion, Ronit , Hill, Brian , Jaeger, Ulrich , Sancho, Juan Manuel , Schuster, Michael , Thieblemont, Catherine , De la Cruz, Fátima , Egyed, Miklos , Mishra, Sourav , Offner, Fritz , Vassilakopoulos, Theodoros , Warzocha, Krzysztof , McCarthy, Daniel , Ma, Xiwen , Corona, Kelly , Saint-Martin, Jean-Richard , Chang, Hua , Landesman, Yosef , Joshi, Anita , Wang, Hongwei , Shah, Jatin , Shacham, Sharon , Kauffman, Michael , Van Den Neste, Eric , Canales, Miguel Ángel M.A.
    Publication 2020-07